Extended-release ketamine tablets offer new hope for treatment-resistant depression

FHS
June 26, 2024
4:17 am

The BEDROC trial found that extended-release ketamine tablets (R-107) significantly improve depressive symptoms in treatment-resistant depression patients, with the 180 mg dose showing the most efficacy. The treatment was well-tolerated with minimal side effects.

Continuing postive momentum 1H’23 – Biotech Investments

Hardman & Co Research Hardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H’23 18-Sep-2023 / 10:40 GMT/BST The issuer is solely responsible

September 19, 2023

Some nonprofit hospitals spend less on charity care than they receive in tax breaks, new analysis shows

A new study of hospitals’ charity care spending suggests nonprofit hospitals really aren’t that different from their for-profit counterparts. One major benefit of being a

March 26, 2024

Arts and creativity interventions prove cost-effective for enhancing older adults’ health and well-being

Study in BMC Public Health evaluates the cost-effectiveness of arts and creativity interventions (ACIs) for older adults, revealing their positive impact on health and well-being,

December 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.